Medical practice valuation services

Practice valuations are rarely academic. They are triggered by events — and the event shapes the analysis:

• — Selling the practice — to a hospital, a private equity platform, or another group; understanding value before the buyer names a number
• — Partner transitions — buy-ins for incoming partners, buy-outs at retirement, and the buy-sell agreement updates that prevent disputes
• — Divorce — where the practice is often the largest marital asset and personal goodwill is contested
• — Estate and gift planning — IRS-compliant valuations for ownership transfers
• — Hospital employment and affiliation — knowing what the practice is worth before negotiating what happens to it
• — Disputes and litigation — shareholder matters requiring an independent expert

The mechanics follow recognized appraisal methodology — income, market, and asset approaches, applied as the facts warrant and reconciled into a conclusion. What distinguishes credible practice valuation is what gets analyzed inside those approaches:

Earnings normalization. Physician compensation must be restated to market rates — the single largest adjustment in most practice valuations, and the one most often done carelessly. Related-party rent, discretionary spending, and non-recurring items follow.

Payer mix and reimbursement risk. A dollar of Medicare revenue, a dollar of commercial revenue, and a dollar of cash-pay revenue carry different durability. Concentration in any payer — or exposure to scheduled reimbursement changes — moves value.

Provider dependency. How much of collections walks out the door if one physician does? Productivity concentration, referral patterns, and the personal-versus-enterprise goodwill question sit at the center of most practice valuations — especially in divorce and partner disputes.

Ancillary economics. In-office ancillaries, infusion and drug revenue, imaging, and facility fees are valued on their own economics — including the regulatory constraints (Stark, Anti-Kickback) that govern whether and how they transfer.

The full engagement process — what we request, how we build the bull and bear cases, how the narrative is constructed — is described on our business valuation page. For ASCs, infusion centers, and other healthcare entities — and for FMV opinions on compensation arrangements — see healthcare business valuation.

Physicians researching a sale usually start with multiples, so it is worth being direct about what the ranges look like — and what they leave out. Ranges observed across recent private-market transactions and industry surveys, expressed against normalized EBITDA:

Treat these as orientation, not appraisal. Platform-scale groups command premiums smaller practices do not; practices below roughly $1 million in earnings often trade on seller's discretionary earnings rather than EBITDA; infusion-heavy specialties require separating drug margin from professional fees; and payer mix, provider count, and growth can push any practice outside its band. The ranges also describe strategic transactions — fair market value for regulatory purposes is a different standard and frequently a different number.

• — Revenue trajectory and the durability of referral relationships
• — Payer mix, contract rates, and reimbursement exposure
• — Provider count and productivity concentration — one-physician risk is the deepest discount in the market
• — Mid-level leverage and capacity utilization
• — Ancillary service lines and their regulatory transferability
• — Real estate: owned, related-party leased, or market leased
• — Staff stability, systems, and the transferability of operations
• — Patient demographics and local market dynamics